JAK2 V617F mutation positive primary myelofibrosis with concomitant t(9;11;22)(q34;p15;q11.2) but no BCR/ABL fusion

被引：0
|
作者：
Wing-Yan Au
Thomas S. K. Wan
Edmond S. K. Ma
机构：
[1] Queen Mary Hospital,Department of Medicine
[2] Queen Mary Hospital,Department of Pathology
[3] Hong Kong Sanatorium & Hospital,Department of Pathology
来源：
International Journal of Hematology | 2013年 / 97卷
关键词：
Imatinib; Tyrosine Kinase Inhibitor; Tenofovir; Chronic Myelogenous Leukemia; Imatinib Mesylate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：435 / 437
页数：2
相关论文
共 50 条
  • [31] An e13a3 BCR-ABL1 fusion transcript in variant t(9;22;17)(q34;q11;q21)-positive adult acute lymphoblastic leukemia
    Zhang, X.
    Pan, J.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 (03) : e52 - e55
  • [32] Saudi Arabian CML patient with a novel four-way translocation at t(9;22;5;2)(q34;q11.2;p13;q44)
    Dridi, Walid
    Kanfar, Solaf
    Sleiman, Patrick M. A.
    Liu, Yichuan
    Hakonarson, Hakon
    Rammah, Hayaal
    Matrouk, Alia
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2022, 10 (06):
  • [33] Coexistence of a heterozygous JAK2(V617F) mutation and a secondary BCR-ABL translocation within the compartment of committed myeloid progenitors in chronic idiopathic myelofibrosis.
    Bornhaeuser, Martin
    Mohr, Brigitte
    Oelschlaegel, Uta
    Bornhauser, Peter
    Jacki, Swen
    Elminger, Gerhard
    Thiede, Christian
    BLOOD, 2006, 108 (11) : 303B - 304B
  • [34] BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease
    Mohamed M Elnaggar
    Sally Agersborg
    Trilochan Sahoo
    Ati Girgin
    Wanlong Ma
    Ronjay Rakkhit
    Isabel Zorrilla
    Alexis Leal
    Molecular Cytogenetics, 5
  • [35] BCR-JAK2 fusion as a result of a translocation (9;22)( p24;q11.2) in a patient with CML-like myeloproliferative disease
    Elnaggar, Mohamed M.
    Agersborg, Sally
    Sahoo, Trilochan
    Girgin, Ati
    Ma, Wanlong
    Rakkhit, Ronjay
    Zorrilla, Isabel
    Leal, Alexis
    MOLECULAR CYTOGENETICS, 2012, 5
  • [36] Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis
    Kronenwett, Ralf
    Graf, Thorsten
    Neumann, Frank
    Pechtel, Sabrina
    Steidl, Ulrich
    Diaz-Blanco, Elena
    Haas, Rainer
    LEUKEMIA RESEARCH, 2006, 30 (10) : 1323 - 1324
  • [37] Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia
    Tirado, Carlos A.
    Chen, Weina
    Huang, Lily Jun-shen
    Laborde, Carrie
    Hiemenz, Matthew C.
    Valdez, Federico
    Ho, Kevin
    Winick, Naomi
    Lou, Zhenjun
    Koduru, Prasad
    LEUKEMIA RESEARCH, 2010, 34 (12) : 1674 - 1676
  • [38] Myeloid neoplasm with eosinophilia and BCR-JAK2/t(9;22)(p24;q11.2) morphologically mimicking chronic myeloid leukemia
    Thakral, Beenu
    Muzzafar, Tariq
    Wang, Sa A.
    Medeiros, L. Jeffrey
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2020, 44
  • [39] Two alternatively spliced 5'BCR/3' JAK2 fusion transcripts in a myeloproliferative neoplasm with a three-way t(9;18;22)(p23;p11.3;q11.2) translocation
    Impera, Luciana
    Lonoce, Angelo
    Fanfulla, Domenica Antonella
    Moreilhon, Chimene
    Legros, Laurence
    Raynaud, Sophie
    Storlazzi, Clelia Tiziana
    CANCER GENETICS, 2011, 204 (09) : 512 - 515
  • [40] Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation
    Oka, Satoko
    Ono, Kazuo
    Nohgawa, Masaharu
    ANNALS OF HEMATOLOGY, 2017, 96 (08) : 1411 - 1413
12345